Skip to content
Dose Brief
Menu
The shortlist

Alternatives to Elara Health and Wellness

Elara Health and Wellness sits at No. 46 in our ranking with a Brief Score of 81. Here are the GLP-1 providers we'd weigh against it — ranked on the same six-factor Brief Score, top down.

Prefer a straight head-to-head? CoreAge Rx vs Elara Health and Wellness.

Our top alternative

No. 1 here

CoreAge Rx

CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Coverage
US only; restrictions by state, confirmed at intake

More providers worth weighing

No. 31 · Grade B−

Direct Meds

82/100

A newer (2024) compounding provider whose real hook is form: it runs an oral/sublingual line alongside the usual injections, on both molecules, with no membership tacked on.

Semaglutide

$249/mo sublingual · $297/mo injectable — both billed monthly on a 3-month minimum commitment

Coverage
Not publicly listed
Price trend
price stable

FDA warning letter, September 2025 — issued to directmeds.com, Inc. dba DirectMeds. See the FDA's warning letter database.

No. 21 · Grade B

MadeMed

86/100

MadeMed publishes quarterly and six-month prices for injectable and sublingual treatment; the full term is prepaid, and supply timing needs confirmation.

Semaglutide

$239/mo injectable

Quarterly prepay: $717 upfront; no monthly plan.

Sublingual: $219/mo, $657 upfront quarterly. Six-month options cost less.

Full price details

$239/mo injectable and $219/mo sublingual on the quarterly plan ($717 / $657 in one charge); $199 and $179 on the 6-month plan. No month-to-month option

Coverage
Availability varies by treatment and state; confirm the selected product before prepaying
Price trend
price stable
No. 62 · Grade C

Clume Health

78/100

Clume combines weight-management programs with optional wellness services, but its starting headline does not establish a price for each GLP-1 medication.

Semaglutide

Confirm current price

Earlier listing: From $259/mo (compounded) (checked September 2026).

Confirm the medication, billing term and full charge before paying.

Full price details

Compounded semaglutide offered. Current medication quote unknown; earlier listing: From $259/mo (compounded)

Coverage
All 50 states and DC claimed, no list published
Price trend
new to the tracker, no prior reading
No. 168 · Grade C

Prime Doctor RX

70/100

Prime Doctor RX names its clinical group and pharmacy, but current medication charges and a nonrefundable consultation deduction need a written quote.

Semaglutide

Confirm medication + consultation

Compounded semaglutide with B12 offered; current medication price and nonrefundable consultation charge need a quote.

Full price details

Compounded semaglutide with B12 offered; current medication and consultation quote unknown; earlier listing: $249 every 4 weeks (compounded)

Coverage
Conditional telehealth availability across all 50 states; glycine formulation is not available in every state
Price trend
new to the tracker, no prior reading
No. 79 · Grade C

MyDrHank

74/100

A six-shelf prescription telehealth catalog whose GLP-1 price genuinely holds flat as you titrate — but whose every advertised figure is a twelve-month prepay rate, with the month-to-month price published nowhere.

Semaglutide

$259/mo (month-to-month; prepay tiers lower)

Coverage
44 states (not KS, LA, MS, NM, ND, WV)
Price trend
new to the tracker, no prior reading
No. 80 · Grade C

Goldspan Health

76/100

Goldspan now describes clinical infrastructure through Altro Health, with compounded GLP-1 options but no complete current medication quote on its reviewed public pages.

Semaglutide

Confirm current price

Earlier listing: from $229 per 28-day cycle. Current medication charge and supply period not confirmed.

Full price details

Compounded semaglutide offered. Current medication quote unknown; earlier observed from $229 per 28-day cycle for compounded semaglutide

Coverage
All 50 states advertised; the terms qualify access by therapy, state and medical history
Price trend
new to the tracker, no prior reading
No. 93 · Grade C

Fitish

75/100

Fitish lists an inclusive $339 monthly tirzepatide supply; refund wording and the next refill's terms deserve confirmation.

Semaglutide

Confirm current price

Earlier listing: $219/mo compounded semaglutide; current product quote could not be reconfirmed.

Full price details

Compounded semaglutide offered. Current medication quote unknown; earlier observed $219/mo compounded; current semaglutide product page was unavailable during review

Coverage
Confirm current prescription-specific state access; no complete coverage list verified
Price trend
new to the tracker, no prior reading

FDA warning letter, June 2026 — issued to FITISH. See the FDA's warning letter database.

No. 9 · Grade B+

REMEVi

87/100

English- and Spanish-language GLP-1 care with four-week billing, published prepaid totals and no advertised dose upcharge.

Semaglutide

$199 / 4 weeks

24-week option: $954 upfront ($159 per four weeks).

Full price details

$199 every 4 weeks; $954 prepaid for 24 weeks ($159 per 4 weeks)

Coverage
49 states and DC; excludes Louisiana
Price trend
new to the tracker, no prior reading

Rankings reflect the Dose Brief Score — our editorial judgment per the methodology. Pricing and coverage reflect public disclosures at last review and change often — confirm on each provider's site. Not medical advice; see our disclosure.